Life Sciences Webinar Series | CREATES Act: What we've learned so far and recommendations for the industry
Related people
Headlines in this article
Related news and insights
News: 04 April 2024
Publications: 20 March 2024
Allen & Overy’s Nicole Daley on the rebound in M&A activity in the pharma industry
News: 15 March 2024
Allen & Overy advises Zendesk on its acquisition of AI-powered service automation leader Ultimate
Publications: 06 March 2024
Shifting Strategies in U.S. Intellectual Property Disputes: Lessons from 2023
In late 2019, Congress enacted the “CREATES Act”, which established a private right of action in which generic or biosimilar manufacturers may sue an innovator for an injunction and monetary award for not selling samples of an innovator product needed for purposes of developing a generic or biosimilar version.
This program will explore the fundamentals of this Act in detail, recent litigation and provide recommendations for innovators to follow when a CREATES request is made.
Date and Time
Thursday, September 29, 2022
12:00 - 1:00 PM EST